We believe that Nintendo’s policy change in 2014 is offering the firm a new growth opportunity, through not limiting its popular characters to game consoles, but expanding them to other platforms—such ...
Adolore BioTherapeutics (”Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the ...
Operating income was $6.2 million in the first quarter of fiscal 2025, compared to $9.7 million in the prior year period. This led to net earnings in Q1 ’25 of $5.1 million, compared to $7.3 million ...